Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05677100 · ClinicalTrials.gov registry record · NA

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

A NA study of Heart Failure and Heart Failure, Congestive, sponsored by Procyrion.

Recruiting
Registry status
NA
Development phase
320
Enrollment target
20
Study locations

NCT05677100: Recruiting NA study of Heart Failure and Heart Failure, Congestive, sponsored by Procyrion.

NCT05677100 is a NA study of Heart Failure and Heart Failure, Congestive that is actively recruiting participants, run by Procyrion. The registered enrollment target is 320 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05677100, a NA study of Heart Failure and Heart Failure, Congestive, is actively recruiting participants, sponsored by Procyrion.

RECRUITING
Registry status
NA
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

Primary Outcome

Incidence of Major Adverse Events

Conditions Studied

Heart Failure Heart Failure, Congestive Heart Failure, Diastolic Heart Failure, Systolic ADHF Heart Failure; With Decompensation Cardiorenal Syndrome

Interventions

  • DEVICE Aortix System

Study Locations (20)

Florida

  • Ascension Sacred Heart - Pensacola
  • Tallahassee Research Institute - Tallahassee
  • University of South Florida - Tampa
  • BayCare Medical/St. Joseph's Hospital - Tampa
  • AdventHealth Tampa - Tampa
  • Cleveland Clinic Florida - Weston

California

  • John Muir Health - Concord
  • Zuckerberg San Francisco General - San Francisco
  • San Francisco Veterans Administration - San Francisco
  • University of California San Francisco - San Francisco

Arizona

  • Banner--University Medical Center Phoenix - Phoenix
  • Mayo Clinic - Arizona - Phoenix
  • HonorHealth Medical Center - Scottsdale

Georgia

  • Emory University Hospital - Atlanta
  • Piedmont Healthcare Inc. - Augusta
  • Wellstar Research Institue - Marietta

Illinois

  • University of Chicago - Chicago
  • Advocate IMMC - Chicago
  • Advocate Aurora - Good Samaritan - Downers Grove

Kansas

  • Ascension via Christi Kansas - Wichita

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2023-08-23
Est. Completion 2027-08
Phase NA
Procyrion

2 total trials

What NCT05677100 shows while recruiting

NCT05677100 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower).

The record links to 7 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Aortix System is the first listed.

NCT05677100 names 20 study sites across 6 states, led by Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05677100 about?

NCT05677100 is a clinical study titled "Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure". Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec...

What is the current status of trial NCT05677100?

This trial is currently recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2023-08-23. Estimated completion is 2027-08.

What conditions does trial NCT05677100 study?

This clinical trial studies the following conditions: Heart Failure, Heart Failure, Congestive, Heart Failure, Diastolic, Heart Failure, Systolic, ADHF.

What interventions are being tested in trial NCT05677100?

The interventions under investigation include: Aortix System (DEVICE).

Who is sponsoring clinical trial NCT05677100?

This trial is sponsored by Procyrion, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05677100 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05677100's enrollment target sits among peer trials

320 134th of 397 higher than 261 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

  • NCT03551951 · 320 participants

    Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05677100

Source: ClinicalTrials.gov NCT05677100, the US trial registry maintained by the National Library of Medicine. NCT05677100 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.